KR880001611A - 벤즈 이미다졸 유도체와 그 제조방법 및 그것을 유효성분으로 하는 의약 조성물 - Google Patents
벤즈 이미다졸 유도체와 그 제조방법 및 그것을 유효성분으로 하는 의약 조성물 Download PDFInfo
- Publication number
- KR880001611A KR880001611A KR1019870008108A KR870008108A KR880001611A KR 880001611 A KR880001611 A KR 880001611A KR 1019870008108 A KR1019870008108 A KR 1019870008108A KR 870008108 A KR870008108 A KR 870008108A KR 880001611 A KR880001611 A KR 880001611A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- compound
- alkyl
- substituted
- formula
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title claims 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims 8
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title claims 2
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 27
- -1 4-substituted-1-piperazinyl Chemical group 0.000 claims 21
- 239000002253 acid Substances 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 229940100198 alkylating agent Drugs 0.000 claims 4
- 239000002168 alkylating agent Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 150000001350 alkyl halides Chemical class 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052744 lithium Inorganic materials 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000005493 quinolyl group Chemical group 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 150000008065 acid anhydrides Chemical class 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000001118 alkylidene group Chemical group 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 125000005956 isoquinolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (17)
- 다음 일반식(I)의 화합물 및 그의 생리학적으로 허용되는 산부가염.상기식에 있어서, R1은 수소원자, 알킬기, 알콕시기, 디알킬 아미노기 또는 할로겐 원자이고, n은 1내지 4이며, R2는 수소원자, 알킬기, 치환 또는 비치환된 아미노 알킬기, 아실기, 치환 또는 비치환된 아르알킬기, 카복시알킬기, 알콕시카보닐알킬기 또는(여기서, X는 치환 또는 비치환된 페닐, 벤질, 벤조일 또는 푸로일기이다)이고, A는 -NR3-(여기서, R3은 수소원자 또는 알킬이다).알킬리덴 또는 알킬렌이며, B는 트리아졸릴, 피리딜, 피리다지닐, 피리미디닐, 피라지닐, 벤즈이미다졸릴, 벤조티아졸릴, 퀴놀릴 및 이소퀴놀릴로부터 선택된 복소환기이고, 이 복소환기는 1개 이상의 알킬기, 알콕시기, 니트로기 또는 페닐기로 임의로 치환된다.
- 제1항에 있어서, R1이 수소원자, 알킬기 또는 알콕시기이고, n이 1또는 2인 화합물.
- 제1항에 있어서, R2가 수소원자, 알킬기, 치환된 아미노알킬기, 아실기, 치환 또는 비치환된 아르알킬기, 카복시알킬기, 알콕시카보닐알킬기 또는 (4-치환된-1-피페라지닐)알킬기인 화합물.
- 제1항에 있어서, R2가 메틸기, 에틸기, 프로필기, 부틸기, 아세틸기, 프로피오닐기, 부티릴기, 스테아로일기, 아미노에틸기, 아미노프로필기, 모노메틸아미노에틸기, 디메틸아미노에틸기, 카복시메틸기, 3-카복시프로필기, 메톡시카보닐메틸기, 에톡시카보닐 메틸기, 벤질기, 펜에틸기, [4-(디메톡시벤조일)-1-피페라지닐]에틸, (4-푸로일-1-피페라지닐)에틸, (4-벤질-1-피페라지닐)에틸, [4-(메톡시페닐) -1-피페라지닐]에틸 또는 4-(에톡시페닐-1-피페라지닐)에틸인 화합물.
- 제1항에 있어서, A가 -NH-, -N(CH3)-, -N(C2H5)-, 메틸렌기, 에틸렌기, 프로필렌기, 부틸렌기, 에틸리덴기, 프로필리덴기 또는 부틸리덴기인 화합물.
- 제1항에 있어서, B가 5-(1,2,3-트리아졸릴), 3-(1,2,4-트리아졸릴), 2-피리딜, 3-피리딜, 4-피리딜, 3-피리다지닐, 4-피리다지닐, 2-피리미디닐, 4-피리미디닐, 5-피리미디닐, 2-피라지닐, 2-벤조이미다졸릴, 2-벤조티아졸릴, 3-벤조이소티아졸릴, 2-퀴놀릴 또는 1-이소퀴놀릴인 화합물.
- 제1항에 있어서, B가 알킬 치환된 피리딜, 알킬 치환된 피리미디닐, 페닐 치환된 피리딜, 니트로 치환된 피리딜 또는 알콕시 치환된 벤저티아졸릴인 화합물.
- 다음 일반식(II)의 화합물을, 다음 일반식(III)의 화합물과 반응시켜, 다음 일반식(Ia')의 화합물을 생성하고, 임의로 알킬화제로 처리하여, R2가 수소가 아닌 다른 치환체인 다음 일반식(Ia)의 화합물로 전환시키거나, 또는 필요에 따라 화합물을 생리학적으로 허용되는 산부가염으로 전환시킴을 특징으로 하여 일반식(Ia)의 화합물 및 그의 생리학적으로 허용되는 산부가염을 제조하는 방법.상기식에 있어서, Ra1은 수소원자, 알킬기 또는 할로겐원자이고, n은 1내지 4이며, Z는 수소원자, 리튬, 나트륨 또는 칼륨이고, R2. A 및 B는 제1항에서 상술한 바와 같다.
- 다음 일반식(IV)의 화합물을, 다음 일반식(III')의 화합물과 반응시킨 다음에 보호기를 제거하여 다음 일반식(I'b)의 화합물을 생성하고, 임의로 알킬화제 또는 아실화제로 처리하여, R2가 수소가 아닌 다른 치환체인 다음 일반식(Ib)의 화합물로 전환시키거나, 또는 필요에 따라 화합물을 생리학적으로 허용되는 산부가염으로 전환시킴을 특징으로 하여 일반식(Ib)의 화합물 그의 생리학적으로 허용되는 산부가염을 제조하는 방법.상기식에 있어서, R1b는 수소원자, 알킬원자, 알콕시기 또는 디알킬아미노기이고, R은 알킬이며, R4는 보호기이고, B1는 피리딜, 피리다지닐, 피리미디닐, 피라지닐, 벤조티아졸릴, 퀴놀릴 및 이소퀴놀리로 부터 선택된 복소환기이며, 이 복소환기는 1개 이상의 알킬기, 알콕시기, 니트로기 또는 페닐기로 임의로 치환되고, Z1는 리튬, 나트륨, 칼륨 또는 디알킬알루미늄이며, A·R2및 n은 제1항에서 상술한 바와 같다.
- 제8항 또는 제9항에 있어서, 알킬화제 및 아실화제가, 알킬할라이드, 아미노알킬할라이드, 아르알킬할라이드, 산무수물, 산할라이드, 알콕시카보닐 알킬할라이드 및 (4-치환된-1-피페라지닐) 알킬할라이드인 제조방법.
- 활성성분으로서 제1항 화합물 또는 그의 생리학적으로 허용되는 산부가염 유효량과 임의로 약학적 제제용 첨가제가 혼합되어 이루어진 의약 조성물.
- 제11항에 있어서, 활성성분이 제2항의 화합물 또는 그의 산부 가염인 의약 조성물.
- 제11항에 있어서, 활성성분이 제3항의 화합물 또는 그의 산부 가염인 의약 조성물.
- 제11항에 있어서, 활성성분이 제4항의 화합물 또는 그의 산부 가염인 의약 조성물.
- 제11항에 있어서, 활성성분이 제5항의 화합물 또는 그의 산부 가염인 의약 조성물.
- 제11항에 있어서, 활성성분이 제6항의 화합물 또는 그의 산부 가염인 의약 조성물.
- 제11항에 있어서, 활성성분이 제7항의 화합물 또는 그의 산부 가염인 의약 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP173759/86 | 1986-07-25 | ||
| JP17375 | 1986-07-25 | ||
| JP17375986 | 1986-07-25 | ||
| JP62171139A JPH0784462B2 (ja) | 1986-07-25 | 1987-07-10 | ベンゾイミダゾ−ル誘導体 |
| JP171139/87 | 1987-07-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR880001611A true KR880001611A (ko) | 1988-04-25 |
| KR960011388B1 KR960011388B1 (ko) | 1996-08-22 |
Family
ID=26493951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019870008108A KR960011388B1 (ko) | 1986-07-25 | 1987-07-25 | 벤즈이미다졸 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4886803A (ko) |
| EP (1) | EP0254322B1 (ko) |
| JP (1) | JPH0784462B2 (ko) |
| KR (1) | KR960011388B1 (ko) |
| AU (1) | AU597696B2 (ko) |
| CA (1) | CA1305481C (ko) |
| DE (1) | DE3781845T2 (ko) |
| ES (1) | ES2044878T3 (ko) |
| FI (1) | FI91152C (ko) |
| NO (1) | NO168770C (ko) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0334809B1 (de) * | 1988-03-21 | 1994-06-15 | Ciba-Geigy Ag | Mittel zum Schutz von Pflanzen gegen Krankheiten |
| US5089592A (en) * | 1988-06-09 | 1992-02-18 | The Dow Chemical Company | Biscyclobutarene monomer comprising two cyclobutarene moieties bridged by a divalent radical comprising at least one benzothiazole or benzimidazole linkage |
| IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| EP0602586B1 (en) * | 1992-12-16 | 1997-06-04 | Takeda Chemical Industries, Ltd. | Stable pharmaceutical composition of fumagillol derivatives |
| US5637724A (en) * | 1995-06-05 | 1997-06-10 | Neurogen Corporation | Substituted aryl and cycloalkyl imidazolones; a new class of GABA brain receptor ligands |
| US5637725A (en) * | 1995-06-05 | 1997-06-10 | Neurogen Corporation | Substituted aryl and cycloalkyl imidazolones; a new class of GABA brain receptor ligands |
| TW381092B (en) * | 1995-07-07 | 2000-02-01 | Otsuka Pharma Co Ltd | Novel benzimidazole derivatives for use in treating arteriosclerotic diseases |
| AU2001236822A1 (en) * | 2000-02-09 | 2001-08-20 | The Procter & Gamble Company | 2-phenylcarbamoyl-benzimidazoles |
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| FR2833494B1 (fr) * | 2001-12-19 | 2006-12-15 | Univ Nantes | Utilisation de composes de la famille des benzamides comme agent immunosuppresseur |
| JP2005289816A (ja) * | 2002-05-14 | 2005-10-20 | Banyu Pharmaceut Co Ltd | ベンズイミダゾール誘導体 |
| CA2503844A1 (en) * | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity |
| EP1479676A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Benzimidazole-derivatives as factor xa inhibitors |
| US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
| NZ551340A (en) * | 2004-04-22 | 2010-10-29 | Boehringer Ingelheim Int | Pharmaceutical composition comprising flibanserin and a melanocortin agonist for the treatment of premenstrual disorder or sexual aversion disorder |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| CA2562763A1 (en) * | 2004-04-23 | 2006-07-20 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
| JP2008511569A (ja) * | 2004-09-03 | 2008-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 注意欠如活動過多障害の治療方法 |
| JP2008531714A (ja) * | 2005-03-04 | 2008-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 不安障害の治療用及び／又は予防用の医薬組成物 |
| JP2008538741A (ja) * | 2005-03-04 | 2008-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 鬱病の治療用及び／又は予防用の医薬組成物 |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| JP2008540356A (ja) * | 2005-05-06 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬物乱用の治療方法 |
| CA2608713A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
| WO2006125042A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug-induced sexual dysfunction |
| PL1912650T3 (pl) | 2005-08-03 | 2018-01-31 | Sprout Pharmaceuticals Inc | Zastosowanie flibanseryny w leczeniu otyłości |
| RU2405770C2 (ru) | 2005-09-27 | 2010-12-10 | Сионоги Энд Ко., Лтд. | Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2 |
| CA2626134C (en) * | 2005-10-29 | 2013-12-24 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| ES2551093T3 (es) * | 2006-05-09 | 2015-11-16 | Sprout Pharmaceuticals, Inc. | Uso de flibanserina para el tratamiento de trastornos del deseo sexual después de la menopausia |
| JP2009541443A (ja) | 2006-06-30 | 2009-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 尿失禁及び関連疾患の治療のためのフリバンセリン |
| WO2008006838A1 (en) * | 2006-07-14 | 2008-01-17 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of sexual disorders in females |
| JP5793828B2 (ja) * | 2006-08-14 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | フリバンセリンの製剤及びその製造方法 |
| CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| EP2056797A2 (en) * | 2006-08-25 | 2009-05-13 | Boehringer Ingelheim International GmbH | Controlled release system and method for manufacturing the same |
| JP5650404B2 (ja) | 2006-12-28 | 2015-01-07 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｎ−置換−ヘテロシクロアルキルオキシベンズアミド化合物およびその使用方法 |
| CL2008002693A1 (es) | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
| EP2473502A1 (en) * | 2009-09-04 | 2012-07-11 | Novartis AG | Heteroaryl compounds as kinase inhibitors |
| NZ627520A (en) | 2010-03-10 | 2015-10-30 | Astrazeneca Ab | 4-phenyl pyridine analogues as protein kinase inhibitors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634704A (en) * | 1983-10-06 | 1987-01-06 | Janssen Pharmaceutica, N.V. | Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines |
-
1987
- 1987-07-10 JP JP62171139A patent/JPH0784462B2/ja not_active Expired - Fee Related
- 1987-07-15 US US07/073,738 patent/US4886803A/en not_active Expired - Lifetime
- 1987-07-16 CA CA000542315A patent/CA1305481C/en not_active Expired - Fee Related
- 1987-07-21 AU AU75965/87A patent/AU597696B2/en not_active Ceased
- 1987-07-21 FI FI873205A patent/FI91152C/fi not_active IP Right Cessation
- 1987-07-23 NO NO873091A patent/NO168770C/no unknown
- 1987-07-24 DE DE8787110741T patent/DE3781845T2/de not_active Expired - Fee Related
- 1987-07-24 ES ES87110741T patent/ES2044878T3/es not_active Expired - Lifetime
- 1987-07-24 EP EP87110741A patent/EP0254322B1/en not_active Expired - Lifetime
- 1987-07-25 KR KR1019870008108A patent/KR960011388B1/ko not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO168770C (no) | 1992-04-01 |
| EP0254322B1 (en) | 1992-09-23 |
| NO873091D0 (no) | 1987-07-23 |
| FI873205A0 (fi) | 1987-07-21 |
| FI91152B (fi) | 1994-02-15 |
| NO168770B (no) | 1991-12-23 |
| JPH0784462B2 (ja) | 1995-09-13 |
| NO873091L (no) | 1988-01-26 |
| FI91152C (fi) | 1994-05-25 |
| AU597696B2 (en) | 1990-06-07 |
| CA1305481C (en) | 1992-07-21 |
| US4886803A (en) | 1989-12-12 |
| DE3781845T2 (de) | 1993-02-18 |
| DE3781845D1 (de) | 1992-10-29 |
| JPS63146871A (ja) | 1988-06-18 |
| EP0254322A1 (en) | 1988-01-27 |
| ES2044878T3 (es) | 1994-01-16 |
| KR960011388B1 (ko) | 1996-08-22 |
| AU7596587A (en) | 1988-01-28 |
| FI873205A (fi) | 1988-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR880001611A (ko) | 벤즈 이미다졸 유도체와 그 제조방법 및 그것을 유효성분으로 하는 의약 조성물 | |
| US4032522A (en) | 2-pyrazinyl-trifluoromethylimidazoles and a method for their preparation | |
| FI964624A0 (fi) | Menetelmä duokarmysiinijohdannaisten stabiloimiseksi | |
| CA2053863A1 (en) | Pyridazinone derivatives | |
| KR880001591A (ko) | 테트라하이드로 나프탈렌 및 인단유도체 | |
| KR900001688A (ko) | 벤조디아제핀 유도체 | |
| KR880011135A (ko) | 콜린성계 상에 작용하는 신규 티아졸 유도체, 그의 제조방법 및 약학 조성물 | |
| KR920021518A (ko) | 피라진 유도체 | |
| IL96811A0 (en) | Heterocyclic derivatives,their preparation and pharmaceutical compositions containing them | |
| KR900001707A (ko) | (아자)나프탈렌설탐 유도체, 그들의 제조 및 그들을 포함한 조성물 | |
| ES8503339A1 (es) | Procedimiento para la obtencion de tetrahidropiridazinonas | |
| KR920002609A (ko) | 티오알킬티오 세팔로스포린 유도체 | |
| KR910009672A (ko) | 피리다진 유도체, 이의 제조방법 및 이것을 함유하는 약학 조성물 | |
| KR900016212A (ko) | 피리딜티아졸리딘 카복스아미드 유도체 및 이의 중간체, 및 이들의 제조방법 | |
| KR890002103A (ko) | 피페리딘 유도체, 그의제법 및 도르지발 38 | |
| ES8104241A1 (es) | Un procedimiento para la preparacion de compuestos derivadosde 1-((naftil substituido)etil)imidazol | |
| KR900004717A (ko) | 이미다졸 부정맥증 치료제 | |
| KR880007491A (ko) | Paf-길항물질인피페라진화합물 | |
| ATE20063T1 (de) | 3-pyridyl-5-alkoxy(oder phenoxy- oder aralkyloxy- )pyrazol-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel. | |
| KR840006342A (ko) | 복소환식 화합물 및 그 제법 | |
| AU562024B2 (en) | (hydroxypropyl) phenoxy (propyl) piperidine | |
| EP0353047A3 (en) | Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents | |
| KR950025044A (ko) | 피리미딘 아사이클로뉴클레오시드 유도체 | |
| KR870008874A (ko) | 4-(2-피리미디닐)-1-피페라지닐 헤테로사이클릭 카보닐유도체 및 그의 제조방법 | |
| JP2547642B2 (ja) | 水溶性ベンゾイミダゾロトリアゾール誘導体またはその塩 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |